{"id":56143,"date":"2024-10-24T07:49:58","date_gmt":"2024-10-24T07:49:58","guid":{"rendered":"https:\/?p=56143"},"modified":"2024-10-24T07:49:58","modified_gmt":"2024-10-24T07:49:58","slug":"viking-therapeutics","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/viking-therapeutics\/","title":{"rendered":"Viking Therapeutics Reports Strong Q3 Results with Promising Clinical Progress"},"content":{"rendered":"

Viking Therapeutics Inc (VKTX)<\/a>, a clinical-stage biopharmaceutical company, recently reported its financial results for the third quarter ending September 30, 2024. This quarter has been pivotal for the company, highlighting substantial advancements in its clinical pipeline, financials, and strategic focus on metabolic and endocrine disorders.<\/p>\n

Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your discount<\/a> here!<\/p>\n

\"Promotion<\/a><\/p>\n

Key Insights from Viking Therapeutics’ Earnings Report:<\/h2>\n

During Q3 2024, Viking Therapeutics demonstrated solid progress in multiple clinical trials. The company plans to meet the U.S. Food and Drug Administration (FDA) at the end of the year to discuss its VK2735 drug targeting obesity. The company is gearing up to initiate a Phase 2 study for an oral version of VK2735 by the end of 2024. Additionally, its ongoing study on VK2809 for treating NASH\/MASH has been recognized with an oral presentation slot at the prestigious American Association for the Study of Liver Diseases (AASLD) conference. Viking Therapeutics reported a strong cash position of $930 million at the end of the quarter, showcasing its financial stability amid high research and development expenses.<\/p>\n

<\/p>\n

\n
\n

VKTX Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n